ProCE Banner Activity

The Gray Zone of Chronic Hepatitis B: To Treat or Not to Treat

Clinical Thought
Deciding which patients with chronic hepatitis B should be treated is not as simple as determining if their ALT and DNA levels fall above guideline thresholds. Here’s my take.

Released: April 06, 2020

Expiration: April 05, 2021

Share

Faculty

Mindie H. Nguyen

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine (GI & Hepatology, Liver Transplant)
Professor of Epidemiology & Population Health
(by Courtesy)
Director of Hepatology Clerkship
Faculty Search LENS Advocates,
Stanford Department of Medicine
Faculty Fellow, Stanford Center for Innovation
in Global Health
Member, Stanford Cancer Institute, Maternal &
Child Health Research Institute, & Stanford Bio-C
Stanford, California
Past Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)
28th President: The International Association for the Study of the Liver (IASL)

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Program Director Disclosure

Program Director

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine (GI & Hepatology, Liver Transplant)
Professor of Epidemiology & Population Health
(by Courtesy)
Director of Hepatology Clerkship
Faculty Search LENS Advocates,
Stanford Department of Medicine
Faculty Fellow, Stanford Center for Innovation
in Global Health
Member, Stanford Cancer Institute, Maternal &
Child Health Research Institute, & Stanford Bio-C
Stanford, California
Past Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)
28th President: The International Association for the Study of the Liver (IASL)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, has disclosed that she has received consulting fees from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, Janssen, Lab for Advance Medicine , Novartis, and Roche and fees for Non-CME/CE Services from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, and Roche.